Zobrazeno 1 - 10
of 17
pro vyhledávání: '"M Schwiening"'
Autor:
P. P. S. J. Khedoe, W. A. A. M. van Schadewijk, M. Schwiening, J. P. Ng-Blichfeldt, S. J. Marciniak, J. Stolk, R. Gosens, P. S. Hiemstra
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 12 (2024)
Externí odkaz:
https://doaj.org/article/aa89c27c4421481493cb8f3fe3ce4887
Autor:
P. P. S. J. Khedoe, W. A. A. M. van Schadewijk, M. Schwiening, J. P. Ng-Blichfeldt, S. J. Marciniak, J. Stolk, R. Gosens, P. S. Hiemstra
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 11 (2023)
Adequate lung epithelial repair relies on supportive interactions within the epithelial niche, including interactions with WNT-responsive fibroblasts. In fibroblasts from patients with chronic obstructive pulmonary disease (COPD) or upon in vitro cig
Externí odkaz:
https://doaj.org/article/6e8b07afb5534fd6992ec59bb2ab9c47
Autor:
M. Schwiening, S. Moore, R. Nibhani, A. Crosby, M. Southwood, B. Dunmore, H. Turton, R. Thompson, N.W. Morrell, S.J. Marciniak, E. Soon
Publikováno v:
D106. HOT OFF THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE.
Autor:
M Schwiening, R Nibhani, S Moore, A Crosby, M Southwood, C Huang, NW Morrell, SJ Marciniak, E Soon
Publikováno v:
‘Inception’ – Embracing complexity in lung science.
Autor:
N Veale, ER Shuvo, M Schwiening, F Soares, O Feng, S Abreu, W Thomas, R Thompson, RJ Samworth, NW Morrell, SJ Marciniak, E Soon
Publikováno v:
‘Infinity War’ – Ongoing clinical challenges in COVID-19.
Publikováno v:
13.01 - Pulmonary hypertension.
Autor:
Elaine Soon, Nicholas W. Morrell, Stefan J. Marciniak, O Feng, ME Shuvo, W Thomas, R Thompson, F Soares, RJ Samworth, M Schwiening
Publikováno v:
Gazing through the crystal ball: predicting outcomes from COVID-19.
Autor:
Abreu S, Keith Burling, N W Morrell, John Wort, Joanna Pepke-Zaba, Emilia M. Swietlik, Elaine Soon, Peter Barker, Stefan Gräf, M Schwiening, Stefan J. Marciniak, Treacy C, Pandya D
BackgroundPulmonary arterial hypertension (PAH) covers a range of life-limiting illnesses characterized by increased pulmonary arterial pressures leading to right heart failure and death, if untreated. 15-25% of patients have genetic mutations, the m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1df1b3843446728bc187cfcd71472ea0
https://doi.org/10.1101/2021.05.05.21253970
https://doi.org/10.1101/2021.05.05.21253970
Autor:
SJ Wort, Joanna Pepke-Zaba, Emilia M. Swietlik, KA Burling, Divya Pandya, Peter Barker, Stefan J. Marciniak, Stefan Gräf, Elaine Soon, Carmen M. Treacy, Nicholas W. Morrell, M Schwiening
Publikováno v:
Pulmonary arterial hypertension: drugs, sox and cytokines.
Background Pulmonary arterial hypertension (PAH) covers a range of life-limiting conditions characterized by increased mean pulmonary arterial pressures leading to right heart failure and eventually death, if left untreated. In approximately 25% of c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.